Acute myocardial infarct size reduction by timolol administration. The International Collaborative Study Group.
A multicenter, randomized, double-blind study was performed to evaluate the effects of timolol administered early during the evolution of acute myocardial infarction. Of 144 patients entered into the trial, 73 were assigned to timolol and 71 to placebo. The 2 groups were well matched at baseline. The timolol group had reduced myocardial ischemia and infarct size as measured by an accelerated reduction of ST-vector magnitude, a significant reduction of creatine kinase (CK) release and significantly smaller changes in QRS vector variables. The predicted maximal QRS vector change and cumulative CK release for any given initial ST-vector magnitude was significantly reduced in the timolol-treated patients. Furthermore, QRS evolution time and CK release time were significantly reduced after intravenous timolol, as were the need for analgesics and the pain scores. Timolol treatment was well tolerated overall.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003402:Creatine Kinase / Q000097:blood; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D011897:Random Allocation; D013999:Timolol / Q000627:therapeutic use*
D013999:Timolol; D003402:Creatine Kinase